Overview

Colchicine for Diabetic Nephropathy

Status:
Unknown status
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Patients with diabetic nephropathy and proteinuria, despite maximal anti- hypertensive and anti-glucose treatment, will receive colchicine for six months, 2 mg a day, during which their 24 hour urine protein and renal function tests will be monitored. The investigators' hypothesis is that colchicine will diminish proteinuria and might also help slow down the development of end stage renal failure in the long run.
Phase:
Phase 2
Details
Lead Sponsor:
Prof.Avi Livneh
Treatments:
Colchicine